DRUG · Mapped RxNorm record
TALAZOPARIB
Normalized identity: talazoparibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
NCT03499353
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedTalazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Early Breast Cancerunresolved
Interventions
TALAZOPARIBDRUG · verified · RxNorm: talazoparib
Sponsors & collaborators
Pfizerlead sponsor
Mapped research locations
AtlantaGeorgia, United States6HoustonTexas, United States4PittsburghPennsylvania, United States4AustinTexas, United States3StanfordCalifornia, United States3ChicagoIllinois, United States2PortlandOregon, United States2DenverColorado, United States2MadisonWisconsin, United States2OrangeCalifornia, United States2DuarteCalifornia, United States2Sioux FallsSouth Dakota, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03499353 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.